GlassScriptPhysician profile
Whitney L Rogers
NPI 1417230004
$8,041.10
in general payments reported to CMS, 2019-2025
30 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,561 · 2022: $1,379 · 2023: $1,682 · 2024: $1,811 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,618 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,618.37 |
| Education | $482.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,554.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,390.93 | 2021-2025 | |
| Janssen Biotech, INC. | $962.47 | 2021-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $805.59 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $608.96 | 2021-2025 | Ilumya |
| Ucb, INC. | $404.78 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $376.76 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $376.25 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $268.55 | 2023-2024 | Vtama |
| Leo Pharma INC. | $232.43 | 2021-2023 | Adbry |
| Genentech USA, INC. | $118.21 | 2021-2022 | |
| Galderma Laboratories, L.P. | $109.15 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $103.63 | 2021 | |
| Pfizer INC. | $101.18 | 2021-2023 | |
| Organon LLC | $83.12 | 2025 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $79.36 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $60.64 | 2022-2024 | Sotyktu |
| Cipher Pharmaceuticals US LLC | $51.25 | 2025 | Natroba, Spinosad |
| Mallinckrodt Hospital Products INC. | $50.64 | 2025 | Acthar |
| Biofrontera INC. | $41.68 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $38.74 | 2023 | Opzelura |
| Almirall LLC | $37.28 | 2022-2023 | Seysara |
| Fresenius Kabi USA, LLC | $32.98 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.63 | 2025 | Spevigo |
| Mayne Pharma Commercial LLC | $29.07 | 2024-2025 | |
| Biowound Solutions, INC. | $26.60 | 2025 | Bio-Connekt |
| Organogenesis INC. | $20.68 | 2023 | Puraply |
| Urgo Medical North America, LLC | $17.75 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Genentech, INC. | $14.09 | 2023 | Erivedge |
| Sandoz INC. | $12.98 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.